Repositioning Candidate Details
| Candidate ID: | R1079 |
| Source ID: | DB06682 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Naproxcinod |
| Synonyms: | (S)-2-(6-Methoxy-2-naphthyl)propanoic acid 4-nitrooxybutyl ester; Naproxen-N-butyl nitrate |
| Molecular Formula: | C18H21NO6 |
| SMILES: | COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCCCO[N+]([O-])=O |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 163133-43-5 |
| Molecular Weight: | 347.367 |
| DrugBank Indication: | Investigated for use/treatment in pain (acute or chronic), inflammatory disorders (unspecified), osteoarthritis, and arthritis and arthritic pain. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |